Сравнение
Cagrilintide vs. Ecnoglutide
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Метаболизм
Метаболизм
Номер CAS
1415456-99-3
нет данных
Молекулярная масса
4253.7 g/mol
нет данных
Период полувыведения
168 h
144 h
Последовательность
KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTYнет данных
Механизм действия
Cagrilintide
Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.
Ecnoglutide
Ecnoglutide is a modified GLP-1(7-37) peptide with an alanine-to-valine substitution at position 8 and an 18-C fatty-acid conjugation at the lysine-30 side chain. It is a so-called biased agonist: at the GLP-1 receptor it preferentially induces cAMP formation while β-arrestin recruitment is reduced. In preclinical models this has been linked to lower receptor internalisation and desensitisation. GLP-1 receptor activation is mechanistically associated with enhanced glucose-dependent insulin secretion, delayed gastric emptying and satiety signalling. The fatty-acid conjugation enables weekly administration via albumin binding.
Доказательная база
Наивысшая доказательность
РКИ на людях
РКИ на людях
Исследования
4
5
из них на людях
3
5
Зафиксированные эффекты
3
4
Открытые противоречия
1
0
Задокументированные нежелательные явления
1
1
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between Cagrilintide and Ecnoglutide?
- Cagrilintide is classified as "Метаболизм", while Ecnoglutide is classified as "Метаболизм". Cagrilintide: Synthetic long-acting amylin analog being developed in combination with semaglutide (CagriSema). Phase 3 trials for obesity and type 2 diabetes are ongoing. No marketing approval yet. Ecnoglutide: Ecnoglutide (XW003) is a long-acting, cAMP-signalling-biased GLP-1 analogue from Sciwind Biosciences. Derived from GLP-1(7-37) with an alanine-to-valine substitution at position 8, it activates the GLP-1 receptor selectively via the cAMP pathway over β-arrestin recruitment. Investigated for weight management and in type 2 diabetes. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Cagrilintide or Ecnoglutide?
- The highest available evidence level is "РКИ на людях" for Cagrilintide and "РКИ на людях" for Ecnoglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Cagrilintide and Ecnoglutide in Germany and the United States?
- Германия: Cagrilintide — Не одобрено, Ecnoglutide — Не одобрено. США: Cagrilintide — Не одобрено, Ecnoglutide — Не одобрено. These are factual summaries with source and review date on the individual pages.